

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2734987

SUBMISSION TYPE:	NEW ASSIGNMENT																												
NATURE OF CONVEYANCE:	SECURITY AGREEMENT																												
CONVEYING PARTY DATA																													
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>QUINTILES TRANSNATIONAL CORP</td> <td>02/06/2014</td> </tr> <tr> <td>OUTCOME SCIENCES, INC.</td> <td>02/06/2014</td> </tr> <tr> <td>TARGETED MOLECULAR DIAGNOSTICS, LLC</td> <td>02/06/2014</td> </tr> </tbody> </table>		Name	Execution Date	QUINTILES TRANSNATIONAL CORP	02/06/2014	OUTCOME SCIENCES, INC.	02/06/2014	TARGETED MOLECULAR DIAGNOSTICS, LLC	02/06/2014																				
Name	Execution Date																												
QUINTILES TRANSNATIONAL CORP	02/06/2014																												
OUTCOME SCIENCES, INC.	02/06/2014																												
TARGETED MOLECULAR DIAGNOSTICS, LLC	02/06/2014																												
RECEIVING PARTY DATA																													
Name:	JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT																												
Street Address:	1111 FANNIN STREET, 10TH FLOOR																												
City:	HOUSTON																												
State/Country:	TEXAS																												
Postal Code:	77002																												
PROPERTY NUMBERS Total: 13																													
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13925377</td> </tr> <tr> <td>Application Number:</td> <td>13925212</td> </tr> <tr> <td>Application Number:</td> <td>13925187</td> </tr> <tr> <td>Application Number:</td> <td>13925229</td> </tr> <tr> <td>Application Number:</td> <td>13925262</td> </tr> <tr> <td>Application Number:</td> <td>13925232</td> </tr> <tr> <td>Application Number:</td> <td>61874511</td> </tr> <tr> <td>Application Number:</td> <td>61879877</td> </tr> <tr> <td>Application Number:</td> <td>61901260</td> </tr> <tr> <td>Application Number:</td> <td>12424943</td> </tr> <tr> <td>Application Number:</td> <td>13857591</td> </tr> <tr> <td>Application Number:</td> <td>13922891</td> </tr> <tr> <td>Application Number:</td> <td>61869424</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13925377	Application Number:	13925212	Application Number:	13925187	Application Number:	13925229	Application Number:	13925262	Application Number:	13925232	Application Number:	61874511	Application Number:	61879877	Application Number:	61901260	Application Number:	12424943	Application Number:	13857591	Application Number:	13922891	Application Number:	61869424
Property Type	Number																												
Application Number:	13925377																												
Application Number:	13925212																												
Application Number:	13925187																												
Application Number:	13925229																												
Application Number:	13925262																												
Application Number:	13925232																												
Application Number:	61874511																												
Application Number:	61879877																												
Application Number:	61901260																												
Application Number:	12424943																												
Application Number:	13857591																												
Application Number:	13922891																												
Application Number:	61869424																												

CORRESPONDENCE DATA

Fax Number:

Email: marina.kelly@thomsonreuters.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: ELAINE CARRERA, LEGAL ASSISTANT

Address Line 1: 80 PINE STREET

Address Line 2: C/O CAHILL GORDON & REINDEL LLP

Address Line 4: NEW YORK, NEW YORK 10005

NAME OF SUBMITTER:	ELAINE CARRERA, LEGAL ASSISTANT
Signature:	/Marina Kelly, Thomson Reuters/
Date:	02/20/2014

Total Attachments: 9

source=Quintiles Patent Security Agreement#page1.tif
source=Quintiles Patent Security Agreement#page2.tif
source=Quintiles Patent Security Agreement#page3.tif
source=Quintiles Patent Security Agreement#page4.tif
source=Quintiles Patent Security Agreement#page5.tif
source=Quintiles Patent Security Agreement#page6.tif
source=Quintiles Patent Security Agreement#page7.tif
source=Quintiles Patent Security Agreement#page8.tif
source=Quintiles Patent Security Agreement#page9.tif

Patent Security Agreement

Patent Security Agreement, dated as of February 6, 2014, by QUINTILES TRANSNATIONAL CORP., OUTCOME SCIENCES, INC. and TARGETED MOLECULAR DIAGNOSTICS, LLC (each a "**Grantor**" and, collectively, the "**Grantors**"), in favor of JPMORGAN CHASE BANK, N.A., in its capacity as administrative agent for the Secured Parties (in such capacity, the "**Administrative Agent**").

WITNESSETH:

WHEREAS, the Grantors are parties to a Security Agreement, dated as of June 8, 2011 (as may be amended, amended and restated, supplemented or otherwise modified from time to time, the "**Security Agreement**"), in favor of the Administrative Agent pursuant to which the Grantors are required to execute and deliver this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent, for the benefit of the Secured Parties, to enter into the Credit Agreement, the Grantors hereby agree with the Administrative Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meaning given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Patent Collateral. Each Grantor hereby pledges and grants to the Administrative Agent for the benefit of the Secured Parties a lien on and security interest in and to all of its right, title and interest in, to and under all the following Pledged Collateral of such Grantor:

- (a) Patents of such Grantor listed on Schedule I attached hereto; and
- (b) all Proceeds of any and all of the foregoing.

SECTION 3. The Security Agreement. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement and Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control unless the Administrative Agent shall otherwise determine.

SECTION 4. Termination. Upon all of the Secured Obligations (other than (x) (i) Cash Management Obligations and (ii) Secured Obligations under Secured Hedge Agreements not yet due and payable, and (y) contingent obligations not yet accrued and payable) having been paid in full, all Letters of Credit having been Cash Collateralized or otherwise backstopped (including by "grandfathering" into any future credit facilities), in each case, on terms reasonably satisfactory to the relevant L/C Issuer in its reasonable discretion, or having expired or having been terminated, and the Aggregate Commitments having expired or having been terminated, and termination of the Security Agreement, this Patent Security Agreement and the security interest granted hereby shall terminate with respect to all of each Grantor's obligations and any lien arising therefrom shall be automatically

released. Upon any sale or transfer by any Grantor of any Patent that is permitted under the Credit Agreement (other than a sale or transfer to another Loan Party), or upon the effectiveness of any written consent to the release of the security interest granted hereby in any Patent pursuant to Section 10.01 of the Credit Agreement, the security interest in such Patent shall be automatically released. The Administrative Agent shall, at the expense of the Grantors, or any of them, execute, acknowledge, and deliver to such Grantors or Grantor within a reasonable time an instrument in writing in recordable form releasing the collateral pledge, grant, assignment, lien and security interest in the Patents, or any of them in the case of a sale or transfer described by the second sentence of this Section 4, under this Patent Security Agreement.


SECTION 5. Counterparts. This Patent Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Patent Security Agreement by signing and delivering one or more counterparts.

[Signature pages follow]

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

QUINTILES TRANSNATIONAL CORP.,
as Grantor

By:


Name: James J. Erlinger III
Title: Executive Vice President,
General Counsel and Secretary


Signature Page to Patent Security Agreement

3765496

PATENT
REEL: 032301 FRAME: 0784

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

OUTCOME SCIENCES, INC.,
as Grantor

By: 
Name: James H. Erlinger III
Title: Secretary


Signature Page to Patent Security Agreement

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

TARGETED MOLECULAR DIAGNOSTICS, LLC,
as Grantor

By: Quintiles Laboratories, LLC,
as Sole Member of Grantor

By: Quintiles, Inc., as Sole Member of
Quintiles Laboratories, LLC


By: 
Name: James H. Erlinger III
Title: Vice President

Signature Page to Patent Security Agreement

3765496

PATENT
REEL: 032301 FRAME: 0786

JPMORGAN CHASE BANK, N.A.,
as Administrative Agent

By: 
Name: Vanessa Chiu
Title: Executive Director

Signature Page to Patent Security Agreement

* 3365496

PATENT
REEL: 032301 FRAME: 0787

Schedule I
to
Patent Security Agreement
U.S. Patent Registrations and Patent Applications

U.S. Patent Applications:

OWNER	APPLICATION NUMBER	DESCRIPTION
Quintiles Transnational Corp.	13/925,377	Methods and Systems for Predictive Clinical Planning and Design and Integrated Execution Services
Quintiles Transnational Corp.	13/925,212	Systems and Methods for Analytics on Viable Patient Populations
Quintiles Transnational Corp.	13/925,187	Systems and Methods for Subject Identification (ID) Modeling
Quintiles Transnational Corp.	13/925,229	Method and System to Manipulate Multiple Selections Against a Population of Elements
Quintiles Transnational Corp.	13/925,262	Systems and Methods for Predictive Analytics for Site Initiation and Patient Enrollment
Quintiles Transnational Corp.	13/925,232	Systems and Methods for Data Visualization
Quintiles Transnational Corp.	61/874,511	Electrical Computing Devices for Recruiting a Patient Population for a Clinical Trial
Quintiles Transnational Corp.	61/879,877	Electrical Computing Devices for Quantification of Differences in medical Treatment Populations
Quintiles Transnational Corp.	61/901,260	Distributed Computing System Providing Personalized Patient Drug Dosing Regimens
Outcome Sciences, Inc.	12/424,943	Apparatus and Methods for determining and processing medical outcomes; Notice of Allowance issued 11/29/13

OWNER	APPLICATION NUMBER	DESCRIPTION
Targeted Molecular Diagnostics, LLC	13/857,591	Compositions and Methods for Reducing Cellular Fat and for Predicting Cardiac Toxicity and upon Treatment with Tyrosine Kinase Inhibitors
Targeted Molecular Diagnostics, LLC	13/922,891	Methods for predicting and/or determining responsiveness to a histone deacetylase (HDAC) inhibitor
Targeted Molecular Diagnostics, LLC	61/869,424	Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (SREBP) pathway